nach oben

International Ophthalmology

Erschienen in:

01.04.2011 | Review

Adalimumab (Humira^™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology

verfasst von: Piergiorgio Neri, Manuela Zucchi, Pia Allegri, Marta Lettieri, Cesare Mariotti, Alfonso Giovannini

Erschienen in: International Ophthalmology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Tumor necrosis factor alpha (TNF-α) is a key soluble mediator involved in the inflammatory cascade of many disorders including uveitis. Among the anti-TNF-α agents, one of the most used in immune-mediated diseases, such as inflammatory arthropathies, is adalimumab (Humira^™, Abbott Pharmaceutical Inc.), a fully humanized antibody. The purpose of this review is to analyze the main pharmacological and clinical aspects of adalimumab and its efficacy both in systemic and ocular inflammatory disorders. Adalimumab was effective in treating several autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. In recent years, adalimumab has been used successfully in refractory cases of intraocular inflammation. Moreover, this biological agent showed good safety and efficacy profiles in ocular use including childhood uveitis. Switching from other anti-TNF-α agents to adalimumab may offer several advantages, such as easier administration, better patient compliance, and lower rate of adverse events. Adalimumab is a promising drug for the therapy of uveitis, although further studies are needed on its application in uveitis.

Vassalli P (1992) The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411–452PubMedCrossRef

Chen G, Goeddel DV (2002) TNF-R1 signaling: a beautiful pathway. Science. 296:1634–1635PubMedCrossRef

Saklatvala J (1986) Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 322:547–549PubMedCrossRef

Selmaj KW, Raine CS (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23:339–346PubMedCrossRef

Nussenblatt RB (1991) Proctor Lecture. Experimental autoimmune uveitis: mechanisms of disease and clinical therapeutic indications. Invest Ophthalmol Vis Sci. 32:3131–3141PubMed

Forrester JV (1992) Duke-Elder lecture: new concepts on the role of autoimmunity in the pathogenesis of uveitis. Eye. 6:433–446PubMed

Caspi RR, Roberge FG, McAllister CG et al (1986) T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J Immunol 136:928–933PubMed

Nakamura S, Yamakawa T, Sugita M et al (1994) The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci. 35:3884–3889PubMed

Sartani G, Silver PB, Rizzo LV et al (1996) Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci. 37:2211–2218PubMed

10.

Santos Lacomba M, Marcos Martin C et al (2001) Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 33:251–255PubMedCrossRef

11.

Ahn JK, Yu HG, Chung H, Park YG (2006) Intraocular cytokine environment in active Behçet uveitis. Am J Ophthalmol 142(3):429–434PubMedCrossRef

12.

Kramer M, Goldenberg-Cohen N, Axer-Siegel R, Weinberger D, Cohen Y, Monselise Y (2005) Inflammatory reaction in acute retinal artery occlusion: cytokine levels in aqueous humor and serum. Ocul Immunol Inflamm. 13(4):305–310PubMedCrossRef

13.

Pérez-Guijo V, Santos-Lacomba M, Sánchez-Hernández M, Castro-Villegas Mdel C, Gallardo-Galera JM, Collantes-Estévez E (2004) Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin 20(2):155–157PubMedCrossRef

14.

Xu Y, Chen W, Lu H, Hu X, Li S, Wang J, Zhao L (2010) The expression of cytokines in the aqueous humor and serum during endotoxin-induced uveitis in C3H/HeN mice. Mol Vis. 16:1689–1695 Aug 21PubMed

15.

Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397–440PubMedCrossRef

16.

Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405PubMedCrossRef

17.

Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259PubMedCrossRef

18.

Lim LL, Fraunfelder FW, Rosenbaum JT (2007) Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthr Rheum 56(10):3248–3252CrossRef

19.

Dick AD, Duncan L, Hale G et al (1998) Neutralizing TNF-αlpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun 11:255–264PubMedCrossRef

20.

Yue C, You X, Zhao L et al (2010) The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int 30(12):1553–1557PubMedCrossRef

21.

Rudwaleit M, Claudepierre P, Wordsworth P et al (2009) Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 36(4):801–808PubMedCrossRef

22.

van den Bosch F, Manger B, Goupille P et al (2010) Effectiveness of adalimumab in treating patients with active psoriatic arthritis (PsA) and predictors of good clinical responses for arthritis, skin, and nail lesions. Ann Rheum Dis 69(2):394–399PubMedCrossRef

23.

Imrie F, Dick AD (2007) Biologics in the treatment of uveitis. Curr Opin Ophthalmol 18:481–486PubMedCrossRef

24.

van Vollenhoven RF (2007) Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis 66:849–851PubMedCrossRef

25.

Dhingra N, Morgan J, Dick AD (2009) Switching biologic agents for uveitis. Eye (Lond) 23(9):1868–1870

26.

Tracey D, Klareskog L, Sasso EH et al (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117(2):244–279PubMedCrossRef

27.

Biester S, Deuter C, Michels H et al (2007) Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 91(3):319–324PubMedCrossRef

28.

Wiens A, Correr CJ, Venson R et al (2010) A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis. Rheumatol Int 30(8):1063–1070

29.

Schmitt J, Wozel G (2009) Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature. Biologics 3:303–318PubMed

30.

van de Putte LBA, Atkins C, Malaise M et al (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63:508–516PubMedCrossRef

31.

den Broeder A, van de Putte LBA, Rau R et al (2002) A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-α antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 29:2288–2298

32.

Keystone EC, Kavanaugh AF, Sharp JT et al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthr Rheum 5:1400–1411CrossRef

33.

Weinblatt ME, Keystone EC, Furst DE et al (2003) Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthr Rheum 1:35–45CrossRef

34.

Weinblatt ME, Keystone EC, Furst DE et al (2006) Long-term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4-year extended study. Ann Rheum Dis 65:753–759PubMedCrossRef

35.

Olivieri I, Scarano E, Gigliotti P et al (2006) Successful treatment of juvenile-onset HLA-B27-associated severe and refractory heel thesitis with adalimumab documented by magnetic resonance imaging. Rheumatology 45(10):1315–1317PubMedCrossRef

36.

Adams AB, Kazim M, Lehman TJA (2005) Treatment of orbital myositis with adalimumab (Humira). J Rheumatol 32:1374–1375PubMed

37.

de Vos AF, van Haren MAC, Verhagen C et al (1994) Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 35:1100–1106PubMed

38.

de Vos AF, van Haren MAC, Verhagen C et al (1995) TNF-induced uveitis in the Lewis rat is associated with intraocular interleukin 6 production. Exp Eye Res 60:199–207PubMedCrossRef

39.

Rosenbaum JT, Howes EL, Rubin RM et al (1988) Ocular inflammatory effects of intravitreally-injected tumor necrosis factor. Am J Pathol 133:47–53PubMed

40.

Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B, Bowman M (2004) Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract 17(1):59–67PubMedCrossRef

41.

Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140:509–516PubMedCrossRef

42.

Avunduk MC, Avunduk AM, Oztekin E et al (2004) Etanercept treatment in the endotoxin-induced uveitis of rats. Exp Eye Res 79:357–365PubMedCrossRef

43.

Koizumi K, Poulaki V, Doehmen S et al (2003) Contribution of TNF-α to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest Ophthalmol Vis Sci 44:2184–2191PubMedCrossRef

44.

Rudwaleit M, Rødevand E, Holck P et al (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 68(5):696–701PubMedCrossRef

45.

Mushtaq B, Saeed T, Situnayake RD et al (2007) Adalimumab for sight-threatening uveitis in Behçet’s disease. Eye (Lond) 21(6):824–825

46.

Takase K, Ohno S, Ideguchi H et al (2011) Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis. Rheumatol Int 31(2):243–245

47.

Diaz-Llopis M, García-Delpech S, Salom D et al (2008) Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 24(3):351–361PubMedCrossRef

48.

Doycheva D, Deuter C, Stuebiger N et al (2007) Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 91(2):180–184PubMedCrossRef

49.

Tynjälä P, Kotaniemi K, Lindahl P et al (2008) Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 47(3):339–344CrossRef

50.

Androudi S, Tsironi E, Kalageropoulos C et al. (2010) Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmol 117(8):1612–1616CrossRef

51.

Robertson M, Liversidge J, Forrester J et al (2003) Neutralising TNF-αlpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 44:3034–3041PubMedCrossRef

Titel: Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology
verfasst von: Piergiorgio Neri
Manuela Zucchi
Pia Allegri
Marta Lettieri
Cesare Mariotti
Alfonso Giovannini
Publikationsdatum: 01.04.2011
Verlag: Springer Netherlands
Erschienen in: International Ophthalmology / Ausgabe 2/2011
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-011-9430-3

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Adalimumab (Humira^™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology

Abstract

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

Extensive unilateral visual field loss due to peripapillary arteriovenous malformation

Isolated foveal hypoplasia: report of a new case and detailed genetic investigation

Isolated optic neuropathy in a case of Behçet’s disease

Correlation between urological alpha1-AR antagonist medication and changed intraoperative iris behavior

Mitomycin C therapy for corneal intraepithelial neoplasia masquerading as limbal stem cell deficiency with recurrent epithelial defect

Orbital dermoid cyst of childhood: clinical pathologic findings, classification and management

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde